CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Vir Biotechnology, Inc. - VIR CFD

    9.65
    2.11%
    0.09
    Low: 9.13
    High: 9.66
    Market Trading Hours* (UTC) Opens on Monday at 14:30

    Mon - Fri: 14:30 - 21:00

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.09
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026235 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026235%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.004012 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.004012%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Vir Biotechnology Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 9.46
    Open* 9.16
    1-Year Change* -67.48%
    Day's Range* 9.13 - 9.66
    52 wk Range 7.72-31.55
    Average Volume (10 days) 1.63M
    Average Volume (3 months) 31.05M
    Market Cap 1.27B
    P/E Ratio -100.00K
    Shares Outstanding 134.52M
    Revenue 118.80M
    EPS -4.49
    Dividend (Yield %) N/A
    Beta 0.37
    Next Earnings Date Feb 21, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 1, 2023 9.66 0.29 3.09% 9.37 9.66 9.07
    Nov 30, 2023 9.46 -0.35 -3.57% 9.81 10.02 9.41
    Nov 29, 2023 9.77 0.15 1.56% 9.62 9.96 9.62
    Nov 28, 2023 9.55 0.22 2.36% 9.33 9.62 9.33
    Nov 27, 2023 9.46 -0.22 -2.27% 9.68 9.68 9.27
    Nov 24, 2023 9.68 -0.04 -0.41% 9.72 10.00 9.66
    Nov 22, 2023 9.80 0.33 3.48% 9.47 9.84 9.47
    Nov 21, 2023 9.39 -0.13 -1.37% 9.52 9.67 9.39
    Nov 20, 2023 9.75 0.09 0.93% 9.66 9.95 9.58
    Nov 17, 2023 9.66 -0.03 -0.31% 9.69 9.88 9.60
    Nov 16, 2023 9.59 0.07 0.74% 9.52 9.67 9.39
    Nov 15, 2023 9.64 -0.13 -1.33% 9.77 10.09 9.55
    Nov 14, 2023 9.84 0.30 3.14% 9.54 9.90 9.22
    Nov 13, 2023 9.13 0.40 4.58% 8.73 9.23 8.48
    Nov 10, 2023 8.75 0.52 6.32% 8.23 8.76 8.11
    Nov 9, 2023 8.10 -0.52 -6.03% 8.62 8.62 8.02
    Nov 8, 2023 8.55 0.28 3.39% 8.27 8.81 8.17
    Nov 7, 2023 8.39 -0.13 -1.53% 8.52 8.67 8.28
    Nov 6, 2023 8.59 -0.14 -1.60% 8.73 8.81 8.51
    Nov 3, 2023 8.72 0.50 6.08% 8.22 9.30 8.22

    Vir Biotechnology, Inc. Events

    Time (UTC) Country Event
    Wednesday, February 21, 2024

    Time (UTC)

    21:00

    Country

    US

    Event

    Q4 2023 Vir Biotechnology Inc Earnings Release
    Q4 2023 Vir Biotechnology Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 1615.8 1095.42 76.368 8.091 10.668
    Revenue 1615.8 1095.42 76.368 8.091 10.668
    Total Operating Expense 782.729 674.664 373.348 186.07 129.36
    Selling/General/Admin. Expenses, Total 161.762 160.793 70.937 37.598 29.131
    Research & Development 474.148 447.506 301.411 147.272 99.129
    Depreciation / Amortization 0.5 0.5 1 1.2 1.1
    Unusual Expense (Income)
    Operating Income 833.068 420.751 -296.98 -177.979 -118.692
    Interest Income (Expense), Net Non-Operating -83.048 138.488 2.836 8.511 2.54
    Other, Net 4.26 -9.437 -4.467 -5.061 -0.212
    Net Income Before Taxes 754.28 549.802 -298.611 -174.529 -116.364
    Net Income After Taxes 515.837 528.584 -298.665 -174.683 -115.884
    Net Income Before Extra. Items 515.837 528.584 -298.665 -174.683 -115.884
    Net Income 515.837 528.584 -298.665 -174.683 -115.884
    Income Available to Common Excl. Extra. Items 515.837 528.584 -298.665 -174.683 -115.884
    Income Available to Common Incl. Extra. Items 515.837 528.584 -298.665 -174.683 -115.884
    Diluted Net Income 515.837 528.584 -298.665 -174.683 -115.884
    Diluted Weighted Average Shares 134.811 133.437 119.159 30.3499 109.397
    Diluted EPS Excluding Extraordinary Items 3.82637 3.9613 -2.50643 -5.75563 -1.0593
    Diluted Normalized EPS 3.82637 3.9613 -2.50643 -5.75563 -1.0593
    Total Extraordinary Items 0
    Cost of Revenue, Total 146.319 65.865
    Gross Profit 1469.48 1029.55
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 3.797 62.957 49.41 374.557 -40.629
    Revenue 3.797 62.957 49.41 374.557 -40.629
    Cost of Revenue, Total 0.022 1.907 5.996 22.253 27.921
    Gross Profit 3.775 61.05 43.414 352.304 -68.55
    Total Operating Expense 218.983 206.328 199.912 179.593 184.593
    Selling/General/Admin. Expenses, Total 47.101 46.778 38.743 43.174 41.59
    Research & Development 171.86 157.643 155.173 114.166 115.082
    Operating Income -215.186 -143.371 -150.502 194.964 -225.222
    Interest Income (Expense), Net Non-Operating 17.93 8.204 25.051 -4.258 -9.19
    Other, Net -0.367 -8.021 -26.187 27.026 0.691
    Net Income Before Taxes -197.623 -143.188 -151.638 217.732 -233.721
    Net Income After Taxes -194.775 -140.956 -101.603 175.312 -76.493
    Net Income Before Extra. Items -194.775 -140.9 -101.603 175.312 -76.493
    Net Income -194.775 -140.9 -101.603 175.312 -76.493
    Income Available to Common Excl. Extra. Items -194.775 -140.9 -101.603 175.312 -76.493
    Income Available to Common Incl. Extra. Items -194.775 -140.9 -101.603 175.312 -76.493
    Diluted Net Income -194.775 -140.9 -101.603 175.312 -76.493
    Diluted Weighted Average Shares 134.059 133.553 133.161 134.963 132.45
    Diluted EPS Excluding Extraordinary Items -1.4529 -1.05501 -0.76301 1.29896 -0.57752
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -1.4529 -1.05501 -0.76301 1.29896 -0.57752
    Minority Interest 0 0.056
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 2519.08 1562.82 772.365 402.995 117.783
    Cash and Short Term Investments 2402.04 708.145 736.861 383.436 98.443
    Cash & Equivalents 848.631 347.815 436.575 109.335 47.598
    Short Term Investments 1553.41 360.33 300.286 274.101 50.845
    Prepaid Expenses 104.356 73.003 27.511 13.378 8.579
    Other Current Assets, Total 12.681 8.594 7.993 6.181 10.761
    Total Assets 2802.09 1954.27 918.761 512.071 191.596
    Property/Plant/Equipment, Total - Net 188.166 130.054 79.893 16.308 12.29
    Property/Plant/Equipment, Total - Gross 208.909 144.546 89.125 21.14 14.006
    Accumulated Depreciation, Total -20.743 -14.492 -9.232 -4.832 -1.716
    Goodwill, Net 16.937 16.937 16.937 16.937 16.937
    Intangibles, Net 32.755 33.287 33.82 35.694 36.917
    Other Long Term Assets, Total 21.226 9.781 15.746 15.847 7.669
    Total Current Liabilities 511.029 341.242 99.064 59.206 39.908
    Accounts Payable 6.422 6.521 5.077 5.881 6.473
    Accrued Expenses 489.09 141.512 76.671 26.258 14.534
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 15.517 193.209 17.051 26.83 18.901
    Total Liabilities 724.125 522.419 201.909 88.129 61.636
    Total Long Term Debt 0 0 0.7 0.9 0
    Deferred Income Tax 3.253 18.439 3.253 3.305 3.305
    Other Liabilities, Total 209.843 162.738 98.892 24.718 18.423
    Total Equity 2077.96 1431.85 716.852 423.942 129.96
    Preferred Stock - Non Redeemable, Net 0 309.137
    Common Stock 0.013 0.013 0.013 0.011 0.004
    Additional Paid-In Capital 1709.83 1571.54 1385.3 793.051 14.669
    Retained Earnings (Accumulated Deficit) 377.237 -138.6 -667.184 -368.519 -193.836
    Unrealized Gain (Loss) -9.122 -1.099 -1.278 -0.601 -0.014
    Total Liabilities & Shareholders’ Equity 2802.09 1954.27 918.761 512.071 191.596
    Total Common Shares Outstanding 133.237 131.161 127.417 107.649 109.397
    Long Term Investments 23.927 201.388 24.29
    Current Port. of LT Debt/Capital Leases 0.265 0.237
    Capital Lease Obligations 0.7 0.9
    Total Receivables, Net 0 773.079
    Accounts Receivable - Trade, Net 0 773.079
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 1769.18 1946.33 2358.63 2519.08 2413.62
    Cash and Short Term Investments 1696.55 1847.43 2250.07 2402.04 2346.48
    Cash & Equivalents 452.1 666.949 824.913 848.631 963.735
    Short Term Investments 1244.45 1180.48 1425.16 1553.41 1382.75
    Total Receivables, Net 0 0
    Accounts Receivable - Trade, Net 0 0
    Prepaid Expenses 59.43 85.736 97.602 104.356 54.18
    Other Current Assets, Total 13.193 13.163 10.957 12.681 12.955
    Total Assets 2044.9 2243.87 2665.94 2802.09 2695.97
    Property/Plant/Equipment, Total - Net 171.931 179.06 185.263 188.166 184.942
    Property/Plant/Equipment, Total - Gross 201.58 204.959 211.512 208.909 203.866
    Accumulated Depreciation, Total -29.649 -25.899 -26.249 -20.743 -18.924
    Goodwill, Net 16.937 16.937 16.937 16.937 16.937
    Intangibles, Net 25.457 25.59 32.622 32.755 32.888
    Other Long Term Assets, Total 21.777 23.597 23.293 21.226 13.485
    Total Current Liabilities 165.05 225.623 485.288 511.029 308.203
    Accounts Payable 3.627 12.362 12.149 6.422 2.722
    Accrued Expenses 146.111 197.58 455.922 489.09 282.616
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 15.312 15.681 17.217 15.517 22.865
    Total Liabilities 369.81 433.666 695.179 724.125 546.115
    Total Long Term Debt 0 0 0 0 0
    Deferred Income Tax 3.253 3.253 18.439
    Other Liabilities, Total 204.76 208.043 206.594 209.843 219.473
    Total Equity 1675.08 1810.21 1970.76 2077.96 2149.85
    Common Stock 0.013 0.013 0.013 0.013 0.013
    Additional Paid-In Capital 1798.82 1771.54 1737.63 1709.83 1682.88
    Retained Earnings (Accumulated Deficit) -121.851 41.562 236.337 377.237 478.84
    Unrealized Gain (Loss) -1.9 -2.903 -3.219 -9.122 -11.88
    Total Liabilities & Shareholders’ Equity 2044.9 2243.87 2665.94 2802.09 2695.97
    Total Common Shares Outstanding 134.498 134.23 133.931 133.237 133.027
    Long Term Investments 39.617 52.358 49.187 23.927 34.102
    Minority Interest 0.044
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line 515.837 528.584 -298.665 -174.683 -115.884
    Cash From Operating Activities 1663.25 -47.589 -190.941 -129.632 -94.096
    Cash From Operating Activities 6.251 5.278 4.4 3.294 1.618
    Amortization 0.532 0.533 1.042 1.223 1.138
    Deferred Taxes -15.186 15.186 -0.052 -0.48
    Non-Cash Items 490.452 31.224 72.812 32.33 7.018
    Changes in Working Capital 665.367 -628.394 29.522 8.204 12.494
    Cash From Investing Activities -1193.46 -140.814 -9.862 -256.158 -60.441
    Capital Expenditures -68.028 -21.817 -6.549 -8.94 -9.935
    Other Investing Cash Flow Items, Total -1125.43 -118.997 -3.313 -247.218 -50.506
    Cash From Financing Activities 34.761 100.331 529.474 449.244 24.978
    Financing Cash Flow Items -1.197 0 -4.248 10.14
    Issuance (Retirement) of Stock, Net 36.218 100.59 533.972 444.872 14.838
    Net Change in Cash 504.553 -88.072 328.671 63.454 -129.559
    Issuance (Retirement) of Debt, Net -0.26 -0.259 -0.25 4.372
    Cash Taxes Paid 252.03
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -140.956 515.837 617.44 442.128 518.621
    Cash From Operating Activities -125.782 1663.25 1628.13 1510.22 550.089
    Cash From Operating Activities 5.505 6.251 4.431 2.882 1.419
    Amortization 0.133 0.532 0.399 0.266 0.133
    Non-Cash Items -1.189 490.452 470.308 474.401 26.002
    Changes in Working Capital 10.725 665.367 535.549 590.548 3.914
    Cash From Investing Activities 98.079 -1193.46 -1040.33 -377.721 -105.392
    Capital Expenditures -6.867 -68.028 -55.432 -36.439 -15.841
    Other Investing Cash Flow Items, Total 104.946 -1125.43 -984.894 -341.282 -89.551
    Cash From Financing Activities 2.344 34.761 32.75 30.765 27.685
    Issuance (Retirement) of Stock, Net 2.31 36.218 34.13 32.086 28.946
    Issuance (Retirement) of Debt, Net -0.066 -0.26 -0.183 -0.124 -0.064
    Net Change in Cash -25.359 504.553 620.551 1163.27 472.382
    Financing Cash Flow Items 0.1 -1.197 -1.197 -1.197 -1.197
    Deferred Taxes -15.186
    Cash Taxes Paid 252.03 191.653
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    SB Investment Advisers (UK) Limited Investment Advisor 12.4275 16684041 -494544 2023-06-30 LOW
    ARCH Venture Partners Venture Capital 9.6213 12916663 3377479 2022-09-09 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 9.3355 12533053 204415 2023-06-30 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 7.6164 10225068 -28854 2023-06-30 LOW
    GSK plc Corporation 6.3694 8550954 0 2023-04-03 LOW
    Scangos (George A) Individual Investor 4.2902 5759638 -1750000 2023-10-17 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.0363 5418804 34641 2023-06-30 LOW
    Temasek Holdings Pte. Ltd. Sovereign Wealth Fund 3.8239 5133610 -681362 2023-06-30 LOW
    Baillie Gifford & Co. Investment Advisor 2.9672 3983445 -2581 2023-06-30 LOW
    AllianceBernstein L.P. Investment Advisor/Hedge Fund 2.0497 2751716 2871 2023-06-30 LOW
    Perceptive Advisors LLC Private Equity 1.4587 1958264 1816070 2023-06-30 MED
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.2594 1690777 165359 2023-06-30 LOW
    Bill & Melinda Gates Foundation Foundation 1.1614 1559142 0 2023-06-30 LOW
    American Century Investment Management, Inc. Investment Advisor/Hedge Fund 1.1021 1479560 116067 2023-06-30 LOW
    Avidity Partners Management LP Hedge Fund 1.0614 1425000 -215200 2023-06-30 HIGH
    Sato (Vicki Lee) Individual Investor 0.9798 1315351 -18000 2023-06-30 LOW
    Renaissance Technologies LLC Hedge Fund 0.8701 1168100 7600 2023-06-30 HIGH
    Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.7618 1022739 977639 2023-06-30 LOW
    Paradigm BioCapital Advisors LP Investment Advisor 0.7555 1014239 1014239 2023-06-30 MED
    Walleye Capital LLC Hedge Fund 0.6431 863380 863380 2023-06-30 HIGH

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Vir Biotechnology Company profile

    Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis. The company has grant agreement with Bill & Melinda Gates Foundation and National Institutes of Health; option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; collaboration and license agreement Alnylam Pharmaceuticals, Inc.; collaboration, license, and option agreement Visterra, Inc.; license agreement with The Rockefeller University and MedImmune, Inc.; and collaboration with WuXi Biologics and Alnylam Pharmaceuticals, Inc. The company has a research collaboration agreement with the National Institutes of Health, the National Institute of Allergy and Infectious Diseases, and Vaccine Research Center to advance characterization and development of human monoclonal antibodies against coronaviruses. It operates in the United States, Oregon, Massachusetts, and Switzerland. The company was founded in 2016 and is headquartered in San Francisco, California.
    Industry: Biotechnology & Medical Research (NEC)

    1800 Owens Street
    Suite 900
    SAN FRANCISCO
    CALIFORNIA 94158
    US

    Income Statement

    • Annual
    • Quarterly

    News

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023
    GBP

    UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

    UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

    10:48, 21 November 2023

    People also watch

    BTC/USD

    40,765.40 Price
    +2.630% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Gold

    2,085.93 Price
    +1.040% 1D Chg, %
    Long position overnight fee -0.0193%
    Short position overnight fee 0.0111%
    Overnight fee time 22:00 (UTC)
    Spread 0.50

    XRP/USD

    0.63 Price
    +0.380% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    Oil - Crude

    74.08 Price
    -0.290% 1D Chg, %
    Long position overnight fee -0.0136%
    Short position overnight fee -0.0083%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading